RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
What are people willing to pay for whole genome sequencing information?
Marshall, DA., Gonzalez, J., Johnson, F., Pugh, A., MacDonald, KV., Douglas, MP., & Phillips, KA. (2015). What are people willing to pay for whole genome sequencing information?Value in Health, 18(3), A285-A285. https://doi.org/10.1016/j.jval.2015.03.1665
Whole genome sequencing (WGS) can be used to predict future disease risk or inform treatment. Current guidelines suggest only reporting variants that are clinically actionable. Reporting incidental or non-actionable findings could generate anxiety and unnecessary medical tests, but patients could miss valuable information if not reported. Over-treatment may occur by acting on findings prematurely, potentially causing harm and unnecessary resource use. We measure the value of WGS information using contingent valuation methods.